Loading stock data…
$26.85-0.63 (-2.29%)
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Amylyx Pharmaceuticals, Inc. in the Healthcare sector is trading at $26.85 with a market capitalization of $3.8B. Wall Street consensus targets $42.36 (11 analysts), implying a +57.8% move over the next 12 months. The stock is currently 35% below its 52-week high of $41.14, remaining 40.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | $0 | $0 | $0 | $0 |
| Operating Income | -$45.69M↓ | -$43.78M↓ | -$36.60M↓ | -$36.03M↑ | -$42.86M |
| Net Income | -$43.42M↓ | -$41.28M↓ | -$33.00M↑ | -$34.39M↑ | -$41.44M |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigation...